6.00p
-0.83%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Poolbeg Pharma
Its shares trade on LSE under the ticker POLB.L. It has been listed since 19 July 2021.
Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The firm is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 002 and POLB 003. The firm is focused on developing two oral delivery platforms targeting areas of unmet medical need that include oral vaccine delivery, which is delivering immune-stimulating antigens to specific areas of the gut using encapsulation technologies, and oral delivery of metabolic disease treatments, which is a delivery system that offers generally regarded as safe (GRAS) approved solution for the oral delivery of GLP-1/metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes and other metabolic diseases. The company uses artificial intelligence to identify infectious disease drug targets and treatments.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Jul 2021
- Employees
- 12
- Website
- poolbegpharma.com ↗
Leadership
Pay as last reported
- Mr. Cathal FrielExecutive Chairman of the Board, since 2021£125,000
- Dr. Jeremy SkillingtonChief Executive Officer, Executive Director, since 2021£305,000
- Mr. Ian OconnellChief Financial Officer, Executive Director, since 2021£190,000
- Prof. Brendan BuckleyIndependent Non-Executive Director£35,000
- Mr. Eddie GibsonIndependent Non-Executive Director£35,000
- Prof. Luke OneillIndependent Non-Executive Director£25,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Poolbeg Pharma focuses on clinical-stage infectious disease pharmaceuticals with POLB 001, POLB 002, and POLB 003 pipelines.
- The company uses AI to identify infectious disease drug targets and treatments effectively.
- Poolbeg Pharma develops oral delivery platforms for gut-targeted immune-stimulating antigens and metabolic disease treatments.
Weaknesses
- Poolbeg Pharma has only 12 employees, which may limit operational capacity.
- The company is listed on the London Stock Exchange since 2021 with limited market presence.
- Poolbeg Pharma's product pipeline is still in clinical stages without commercialized products.
Opportunities
- The global pharmaceutical market for infectious diseases offers significant growth potential.
- Poolbeg Pharma's oral delivery platforms could expand into diabetes and metabolic disease treatments.
- AI-driven drug discovery presents opportunities for faster development of new treatments.
Threats
- Competition in the pharmaceutical sector may increase with new entrants targeting infectious diseases.
- Regulatory hurdles could delay the approval of clinical-stage products like POLB 001.
- The high cost of clinical trials may strain financial resources for a small company like Poolbeg Pharma.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.